Page 65 - Programme book for The International Liver Congress 2015, EASL ILC 2015
P. 65
Parallel Session: Viral Hepatitis C: Therapy Hall D
Chairs:
Alessio Aghemo, Italy
Maria Buti, Spain
ABSTRACT C-SALVAGE: GRAZOPREVIR (GZR; MK-5172), ELBASVIR SCIENTIFIC PROGRAMME
O001 (EBR; MK-8742) AND RIBAVIRIN (RBV) FOR CHRONIC
16:00 - 16:15 HCV-GENOTYPE 1 (GT1) INFECTION AFTER FAILURE OF
DIRECT-ACTING ANTIVIRAL (DAA) THERAPY
ABSTRACT Xavier Forns, Spain
O002
16:15 - 16:30 TREATMENT OF DECOMPENSATED HCV CIRRHOSIS
IN PATIENTS WITH DIVERSE GENOTYPES: 12 WEEKS
ABSTRACT SOFOSBUVIR AND NS5A INHIBITORS WITH/WITHOUT
O003 RIBAVIRIN IS EFFECTIVE IN HCV GENOTYPES 1 AND 3
16:30 - 16:45 Graham Foster, The United Kingdom
ABSTRACT CAN HEPATITIS C TREATMENT BE SAFELY DELAYED?:
O004 EVIDENCE FROM THE VETERANS ADMINISTRATION
16:45 - 17:00 HEALTHCARE SYSTEM
Jeffrey S. Mc Combs, The United States
ABSTRACT
O005 ON-TREATMENT VIROLOGIC RESPONSE AND
17:00 - 17:15 TOLERABILITY OF SIMEPREVIR, DACLATASVIR AND
RIBAVIRIN IN PATIENTS WITH RECURRENT HEPATITIS C
VIRUS GENOTYPE 1B INFECTION AFTER ORTHOTOPIC
LIVER TRANSPLANTATION (OLT): INTERIM DATA FROM
THE PHASE II SATURN STUDY
Xavier Forns, Spain
RETREATMENT OF PATIENTS WHO FAILED 8 OR
12 WEEKS OF LEDIPASVIR/SOFOSBUVIR-BASED
REGIMENS WITH LEDIPASVIR/SOFOSBUVIR FOR 24
WEEKS
Eric Lawitz, The United States
Vienna, Austria • April 22–26, 2015 65
Chairs:
Alessio Aghemo, Italy
Maria Buti, Spain
ABSTRACT C-SALVAGE: GRAZOPREVIR (GZR; MK-5172), ELBASVIR SCIENTIFIC PROGRAMME
O001 (EBR; MK-8742) AND RIBAVIRIN (RBV) FOR CHRONIC
16:00 - 16:15 HCV-GENOTYPE 1 (GT1) INFECTION AFTER FAILURE OF
DIRECT-ACTING ANTIVIRAL (DAA) THERAPY
ABSTRACT Xavier Forns, Spain
O002
16:15 - 16:30 TREATMENT OF DECOMPENSATED HCV CIRRHOSIS
IN PATIENTS WITH DIVERSE GENOTYPES: 12 WEEKS
ABSTRACT SOFOSBUVIR AND NS5A INHIBITORS WITH/WITHOUT
O003 RIBAVIRIN IS EFFECTIVE IN HCV GENOTYPES 1 AND 3
16:30 - 16:45 Graham Foster, The United Kingdom
ABSTRACT CAN HEPATITIS C TREATMENT BE SAFELY DELAYED?:
O004 EVIDENCE FROM THE VETERANS ADMINISTRATION
16:45 - 17:00 HEALTHCARE SYSTEM
Jeffrey S. Mc Combs, The United States
ABSTRACT
O005 ON-TREATMENT VIROLOGIC RESPONSE AND
17:00 - 17:15 TOLERABILITY OF SIMEPREVIR, DACLATASVIR AND
RIBAVIRIN IN PATIENTS WITH RECURRENT HEPATITIS C
VIRUS GENOTYPE 1B INFECTION AFTER ORTHOTOPIC
LIVER TRANSPLANTATION (OLT): INTERIM DATA FROM
THE PHASE II SATURN STUDY
Xavier Forns, Spain
RETREATMENT OF PATIENTS WHO FAILED 8 OR
12 WEEKS OF LEDIPASVIR/SOFOSBUVIR-BASED
REGIMENS WITH LEDIPASVIR/SOFOSBUVIR FOR 24
WEEKS
Eric Lawitz, The United States
Vienna, Austria • April 22–26, 2015 65
